JAZZ (Jazz Pharmaceuticals) Float Percentage Of Total Shares Outstanding: 97.04% (As of Jul. 11, 2026)


JAZZ Jazz Pharmaceuticals PLC JAZZ
73 GF Score
Price $243.79
GF Value $150.80
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Jazz Pharmaceuticals JAZZ -1.25% 73 Float Percentage Of Total Shares Outstanding is 97.04% as of Jul. 11, 2026. GuruFocus rates JAZZ with a GF Score™ of 73/100 and a GF Value™ of $150.80 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Jazz Pharmaceuticals's float shares is 60.96 Mil. Jazz Pharmaceuticals's total shares outstanding is 62.82 Mil. Jazz Pharmaceuticals's float percentage of total shares outstanding is 97.04%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Jazz Pharmaceuticals's Insider Ownership is 5.81%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Jazz Pharmaceuticals's Institutional Ownership is 113.88%.

JAZZ
73GF Score
Jazz Pharmaceuticals PLC JAZZ
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Jazz Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=60.96/62.82
=97.04%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 97.04% mean?
Jazz Pharmaceuticals (JAZZ) has a Float Percentage Of Total Shares Outstanding of 97.04% as of Jul. 11, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Float Percentage Of Total Shares Outstanding too high?
Jazz Pharmaceuticals' current Float Percentage Of Total Shares Outstanding is 97.04%. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Float Percentage Of Total Shares Outstanding compare to BBIO and EXEL?
Jazz Pharmaceuticals' Float Percentage Of Total Shares Outstanding of 97.04% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Float Percentage Of Total Shares Outstanding is 97.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (JAZZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $150.80, compared to a current price of $243.79 — trading 61.7% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 97.04%. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Jazz Pharmaceuticals (JAZZ), the current Float Percentage Of Total Shares Outstanding is 97.04% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (JAZZ) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of $243.79 is trading 61.7% above its estimated GF Value™ of $150.80. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for JAZZ:

  • Float Percentage Of Total Shares Outstanding: 97.04%
  • GF Value™: $150.80 vs. price of $243.79 (61.7% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the JAZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for JAZZ

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$243.79
Price
$150.80
GF Value